These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 25858958)

  • 1. Neuraminidase: Another Piece of the Influenza Vaccine Puzzle.
    Eckard LE; Webby RJ
    J Infect Dis; 2015 Oct; 212(8):1180-1. PubMed ID: 25858958
    [No Abstract]   [Full Text] [Related]  

  • 2. NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
    Krammer F; Fouchier RAM; Eichelberger MC; Webby RJ; Shaw-Saliba K; Wan H; Wilson PC; Compans RW; Skountzou I; Monto AS
    mBio; 2018 Apr; 9(2):. PubMed ID: 29615508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine.
    Chen GL; Subbarao K
    Nat Med; 2009 Nov; 15(11):1251-2. PubMed ID: 19893556
    [No Abstract]   [Full Text] [Related]  

  • 4. Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target.
    Schneider C; Coughlan L
    Mol Ther; 2023 Jul; 31(7):1865-1867. PubMed ID: 37201525
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
    Petrie JG; Ohmit SE; Johnson E; Truscon R; Monto AS
    J Infect Dis; 2015 Dec; 212(12):1914-22. PubMed ID: 26014800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating the potential effects of a vaccine program against an emerging influenza pandemic--United States.
    Biggerstaff M; Reed C; Swerdlow DL; Gambhir M; Graitcer S; Finelli L; Borse RH; Rasmussen SA; Meltzer MI; Bridges CB
    Clin Infect Dis; 2015 May; 60 Suppl 1(Suppl 1):S20-9. PubMed ID: 25878298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.
    Wohlbold TJ; Nachbagauer R; Margine I; Tan GS; Hirsh A; Krammer F
    Vaccine; 2015 Jun; 33(29):3314-21. PubMed ID: 26026378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular signatures of vaccine adjuvants.
    Olafsdottir T; Lindqvist M; Harandi AM
    Vaccine; 2015 Sep; 33(40):5302-7. PubMed ID: 25989447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Error-prone pcr-based mutagenesis strategy for rapidly generating high-yield influenza vaccine candidates.
    Ye J; Wen F; Xu Y; Zhao N; Long L; Sun H; Yang J; Cooley J; Todd Pharr G; Webby R; Wan XF
    Virology; 2015 Aug; 482():234-43. PubMed ID: 25899178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focused antibody response to influenza linked to antigenic drift.
    Huang KY; Rijal P; Schimanski L; Powell TJ; Lin TY; McCauley JW; Daniels RS; Townsend AR
    J Clin Invest; 2015 Jul; 125(7):2631-45. PubMed ID: 26011643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive Mutations That Occurred during Circulation in Humans of H1N1 Influenza Virus in the 2009 Pandemic Enhance Virulence in Mice.
    Otte A; Sauter M; Daxer MA; McHardy AC; Klingel K; Gabriel G
    J Virol; 2015 Jul; 89(14):7329-37. PubMed ID: 25948752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral Interference: The Case of Influenza Viruses.
    Schultz-Cherry S
    J Infect Dis; 2015 Dec; 212(11):1690-1. PubMed ID: 25943204
    [No Abstract]   [Full Text] [Related]  

  • 13. Adaptation of avian influenza A (H6N1) virus from avian to human receptor-binding preference.
    Wang F; Qi J; Bi Y; Zhang W; Wang M; Zhang B; Wang M; Liu J; Yan J; Shi Y; Gao GF
    EMBO J; 2015 Jun; 34(12):1661-73. PubMed ID: 25940072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of MDCK Stable Cell Lines Expressing TMPRSS2 and MSPL and Their Applications in Propagating Influenza Vaccine Viruses in Absence of Exogenous Trypsin.
    Wen Z; Wu C; Chen W; Zeng X; Shi J; Ge J; Chen H; Bu Z
    Biotechnol Res Int; 2015; 2015():402628. PubMed ID: 25918647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer vaccines.
    Butterfield LH
    BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemagglutinin clusters in the plasma membrane are not enriched with cholesterol and sphingolipids.
    Wilson RL; Frisz JF; Klitzing HA; Zimmerberg J; Weber PK; Kraft ML
    Biophys J; 2015 Apr; 108(7):1652-1659. PubMed ID: 25863057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.
    Lopez CE; Zacharias ZR; Ross KA; Narasimhan B; Waldschmidt TJ; Legge KL
    NPJ Vaccines; 2024 May; 9(1):96. PubMed ID: 38822003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.
    Lopez CE; Legge KL
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32756443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungs.
    Dutta A; Huang CT; Lin CY; Chen TC; Lin YC; Chang CS; He YC
    Sci Rep; 2016 Sep; 6():32973. PubMed ID: 27596047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR674 inhibits the neuraminidase-stimulated immune response on dendritic cells via down-regulated Mbnl3.
    Lin J; Chen YT; Xia J; Yang Q
    Oncotarget; 2016 Aug; 7(31):48978-48994. PubMed ID: 27285980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.